부산대학교 도서관

BACKGROUND: Risperidone and olanzapine are thought to have similar clinical effects. This study was designed to compare costs of treatment. AIM: To compare costs of treatment with risperidone or olanzapine in a naturalistic setting. METHOD: The Irish Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme was a retrospective review of medical notes and prescription charts in 396 inpatients with schizophrenia or schizoaffective disorder. The main outcome measure was cost of inpatient drug treatment. RESULTS: There was no statistical difference in length of hospital stay between risperidone-treated and olanzapinetreated patients (mean duration of stay 37.8 and 40.5 days, p=0.90). Mean±SD doses of risperidone and olanzapine were 4.2±2.1mg/day and 12.9±5.0mg/day, respectively. Average daily cost of all inpatient drugs was significantly higher for olanzapine than for risperidone (i.e. IEP5.61 [€7.12] vs IEP3.38 [€4.29]; p<0.0001), as was mean total costs of all inpatient drugs (i.e. IEP114.8 [€145.8] vs IEP62.0 [€78.7]; p<0.0001). This partly reflected the mean, nonsignificant, longer treatment duration for olanzapine compared with risperidone (mean 30.0 vs 26.4 days; p=0.27). Concomitant n€leptic use was similar for both groups (71% risperidone, 73% olanzapine; p=0.54). CONCLUSION: Risperidone was associated with significantly lower drug treatment costs.